Anticancer ruthenium(ii) tris(pyrazolyl)methane complexes with bioactive co-ligands

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

Alberto Gobbo; Lorenzo Biancalana; Stefano Zacchini; M. Lúcia M. F. S. Saraiva; Paul J. Dyson; Fabio Marchetti

doi:10.1039/d2dt03009h

Anticancer ruthenium(ii) tris(pyrazolyl)methane complexes with bioactive co-ligands

Alberto Gobbo & Fabio Marchetti et al. · 2022-11-15

8Citations

New anticancer Ru^II-tpm complexes are presented, including a synthetic strategy to tether bioactive molecules to the metallic scaffold.

Links

DOI PubMed

Journal

Dalton Transactions

TL;DR

The {Ru-tpm-PPh3} assembly is stable in D2O and in biological medium (DMEM) at 37 °C, with a tendency to slowly dissociate the pyridine ligand, and the antiproliferative activity of the complexes was assessed on the cancerous A27 80 and A2780cisR cell lines and the nontumoral HEK 293T cell line.

AI-generated by Semantic Scholar

Anticancer ruthenium(ii) tris(pyrazolyl)methane complexes with bioactive co-ligands

Links

Journal

TL;DR

Institutions

Authors

Funding